Search Medical Condition
Please enter condition
Please choose location
Clear Trial Filters
 

Cystic Fibrosis Clinical Trials

A listing of Cystic Fibrosis medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (9) clinical trials

First-in-man Dose Escalation Study of ALX-009 and Its Components in Healthy Men and Cystic Fibrosis Suffering Patients

Part I: SAD of OSCN- and bLF in healthy male volunteers (cohorts 1 to 3) - Part II: SAD and MAD of ALX-009 in healthy male volunteers (cohorts 4 and 5) - Part III: MAD of OSCN- and bLF in patients suffering from cystic fibrosis (cohorts 6 to 8) - ...

Phase

Autologous CD117+ Progenitor Cell Mobilization for Lung Transplantation

The investigators have developed a new therapy utilizing a stem cell found in the bone marrow that is defined by cell surface expression of the protein "cluster of differentiation antigen 117" (CD117). Studies utilizing these stem cells in a mouse heart transplant model have demonstrated significantly improved survival of transplanted ...

Phase

Ocular Surface Changes in Patients With Cystic Fibrosis

The aim: To assess the role of chosen parameters of immunological response in the induction of ocular changes in cystic fibrosis patients, particularly chosen chemokine concentrations in the tear fluid and analysis of chosen apoptotic markers expression on conjunctival epithelial cells.

Phase

MAD Study Evaluating the Safety Tolerability and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

This study will assess the safety and tolerability of escalating, multiple ascending doses of Cavosonstat (N91115) in healthy subjects. Approximately 5 ascending cohorts are planned with approximately 8 subjects per cohort (6 active, 2 placebo). Each subject will undergo screening (Day -28 to Day -2) and, if eligible, return to ...

Phase

A Study to Assess the Effect of AZD5634 on Mucociliary Clearance Safety Tolerability and Pharmacokinetic Parameters in Patients With Cystic Fibrosis

The primary pharmacodynamic endpoint will be the average whole lung particle clearance between 0 and 60 minutes after administration of aerosolized radiolabelled particles (colloids) at Visits 2 and 3 (%MCC 0-60, whole).

Phase